315 related articles for article (PubMed ID: 25399825)
1. Development of novel activin-targeted therapeutics.
Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA
Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825
[TBL] [Abstract][Full Text] [Related]
2. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
3. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.
Souza TA; Chen X; Guo Y; Sava P; Zhang J; Hill JJ; Yaworsky PJ; Qiu Y
Mol Endocrinol; 2008 Dec; 22(12):2689-702. PubMed ID: 18927237
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease.
Chen JL; Walton KL; Hagg A; Colgan TD; Johnson K; Qian H; Gregorevic P; Harrison CA
Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5266-E5275. PubMed ID: 28607086
[TBL] [Abstract][Full Text] [Related]
6. Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.
Aykul S; Martinez-Hackert E
J Biol Chem; 2016 May; 291(20):10792-804. PubMed ID: 26961869
[TBL] [Abstract][Full Text] [Related]
7. The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy.
Ohsawa Y; Takayama K; Nishimatsu S; Okada T; Fujino M; Fukai Y; Murakami T; Hagiwara H; Itoh F; Tsuchida K; Hayashi Y; Sunada Y
PLoS One; 2015; 10(7):e0133713. PubMed ID: 26226340
[TBL] [Abstract][Full Text] [Related]
8. Activin receptor signaling: a potential therapeutic target for osteoporosis.
Lotinun S; Pearsall RS; Horne WC; Baron R
Curr Mol Pharmacol; 2012 Jun; 5(2):195-204. PubMed ID: 21787285
[TBL] [Abstract][Full Text] [Related]
9. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
[TBL] [Abstract][Full Text] [Related]
10. TGFβ Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice.
Pan C; Singh S; Sahasrabudhe DM; Chakkalakal JV; Krolewski JJ; Nastiuk KL
Endocrinology; 2016 Nov; 157(11):4461-4472. PubMed ID: 27611336
[TBL] [Abstract][Full Text] [Related]
11. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
Chiu CS; Peekhaus N; Weber H; Adamski S; Murray EM; Zhang HZ; Zhao JZ; Ernst R; Lineberger J; Huang L; Hampton R; Arnold BA; Vitelli S; Hamuro L; Wang WR; Wei N; Dillon GM; Miao J; Alves SE; Glantschnig H; Wang F; Wilkinson HA
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1181-92. PubMed ID: 23525481
[TBL] [Abstract][Full Text] [Related]
12. An activin-A/C chimera exhibits activin and myostatin antagonistic properties.
Muenster U; Harrison CA; Donaldson C; Vale W; Fischer WH
J Biol Chem; 2005 Nov; 280(44):36626-32. PubMed ID: 16129674
[TBL] [Abstract][Full Text] [Related]
13. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
[TBL] [Abstract][Full Text] [Related]
14. Generation of a specific activin antagonist by modification of the activin A propeptide.
Makanji Y; Walton KL; Chan KL; Gregorevic P; Robertson DM; Harrison CA
Endocrinology; 2011 Oct; 152(10):3758-68. PubMed ID: 21750050
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.
Rahimov F; King OD; Warsing LC; Powell RE; Emerson CP; Kunkel LM; Wagner KR
Physiol Genomics; 2011 Apr; 43(8):398-407. PubMed ID: 21266502
[TBL] [Abstract][Full Text] [Related]
16. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Han HQ; Zhou X; Mitch WE; Goldberg AL
Int J Biochem Cell Biol; 2013 Oct; 45(10):2333-47. PubMed ID: 23721881
[TBL] [Abstract][Full Text] [Related]
17. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.
Schneyer AL; Sidis Y; Gulati A; Sun JL; Keutmann H; Krasney PA
Endocrinology; 2008 Sep; 149(9):4589-95. PubMed ID: 18535106
[TBL] [Abstract][Full Text] [Related]
18. Prodomains regulate the synthesis, extracellular localisation and activity of TGF-β superfamily ligands.
Harrison CA; Al-Musawi SL; Walton KL
Growth Factors; 2011 Oct; 29(5):174-86. PubMed ID: 21864080
[TBL] [Abstract][Full Text] [Related]
19. An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors.
Harrison CA; Gray PC; Fischer WH; Donaldson C; Choe S; Vale W
J Biol Chem; 2004 Jul; 279(27):28036-44. PubMed ID: 15123686
[TBL] [Abstract][Full Text] [Related]
20. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
